ASML equity deep research on EUV lithography monopoly, High-NA EUV growth, semiconductor equipment cycles, export controls, and whether ASML can turn optics, precision mechanics, metrology, and software capabilities into a broader manufacturing platform.
Q1 FY26 ServiceNow delivered a contradictory report card: cRPO +22.5% surpassing Q4, Now Assist $1M+ ACV customers +130%, Q1 buybacks of $2.225B — but Q2 cRPO guide fell to 19%, Q2 Adj OM guide is only 26.5%, the Middle East created a 75bps deferral, and Armis integration adds 125bps of pressure. More critically, the timing: on 4/10, UBS downgraded the stock (Buy→Neutral, price target $170→$100, cRPO estimate 20%→16%) and shares surged on 47M volume with a long lower shadow at $81.40; 12 days later, Q1's actual +22.5% overturned UBS.
On the day UBS downgraded NOW (Buy→Neutral, price target $170→$100, cRPO estimate 20%→16%), shares surged on 47M volume (2x average) closing with a long lower shadow at $81.40 — traditional data and smart money facing off on the same day. Over the following 8 days, accumulation carried the stock to $103.07, and Q1 FY26 cRPO of +22.5% overturned the UBS downgrade. v2.1 upgrades to a Stage 3 core position-building determination, while reinforcing moat data (97% renewal, 228x for the 2011 cohort, Now Assist $1M+ ACV +130%).
Accenture isn't selling software — it's selling the implementation capability that makes AI actually work. While every enterprise talks about digital transformation, ACN is the one turning plans into reality, with a moat built on a repeatable delivery system.
Reddit is undergoing a fundamental business-model transformation — upgrading from an advertising platform into an AI-era data infrastructure company. Twenty years of user discussion data have become a scarce asset for LLM training, with estimated data-licensing revenue of $400M+/year, fundamentally reshaping its valuation logic. A dual-monetization model — advertising plus data licensing as twin engines — gives this scarce asset strong pricing power.
This article is the original research version from March 31, 2026, written before Claude Design launched. The core thesis at the time: Figma is an 'AI beneficiary whose moat is being reinforced,' with Anthropic viewed as a strategic ally and Google Stitch as the biggest threat. Preserved as a historical record of how the research evolved.
Claude Design launched on 2026.04.17, and FIG fell 5-6% in a single day. But the market misidentified the opponent: Claude Design is attacking Canva's entry point, while Figma sells organizational collaboration order. The two are not competing on the same dimension. This article updates the moat assessment and valuation scenarios, restoring the real risk picture for FIG.
No advanced chip can be designed without EDA tools. Cadence is one half of this essential tool-chain duopoly. Is AI a multiplier or an ender for the business? How dangerous are China export controls, really? What does a $7.8B backlog actually tell you?
Cloudflare builds the highway, Zscaler runs the tollbooth. Which side should you back in the age of AI agents? MarketSurge live data, a nine-metric financial head-to-head, five-year scenario valuations, and a dual Four-Layer Defensive Screen evaluation. Both stocks carry an EPS Rating of 98 and an SMR of A — yet their P/S ratios differ by 4x.
A complete Cloudflare (NET) top-down deep-dive: the three industry maps of SASE/Zero Trust/edge computing, a six-way competitive landscape analysis, the core narrative across four quarterly earnings calls, eight quarters of financial trends, an in-depth Anthropic Mythos SWOT analysis, and a 25-term glossary at the end. Based on FY2024/2025 annual reports and earnings-call transcripts.
ServiceNow boasts a 98% renewal rate and $4.6 billion in annual free cash flow, but Agentic AI is dismantling the per-seat billing foundation it has relied on. A full update after the Claude Mythos event: the Four-Layer Defensive Screen assessment, the five-layer moat, and a breakdown of the Veza/Armis acquisitions. Overall call: passively watching.
Zscaler is down 38% YTD in 2026 as the market misreads AI as a replacement for cybersecurity. Five layers of moat, AI Security ARR hit ahead of schedule, and a full Four-Layer Defensive Screen assessment. Includes an update on the April 2026 Claude Mythos event.
In this series, Tempus sells data, Veeva collects a toll, and SDGR bets on the future. Illumina is the least glamorous name of them all — it sells the shovels. But when everyone is panning for gold, the shovel seller is often the one laughing last.
While the market debates how AI is changing drug discovery, Schrödinger has already positioned itself elsewhere — it doesn't need its own drug to succeed; it only needs "someone" to succeed to share in the payoff. This isn't a company. It's a payoff structure.
While the market obsesses over AI transforming drug discovery, Veeva is doing something else entirely — making sure that no matter who discovers the drug, they have to go through its system. This isn't a growth stock. It's the industry's toll gate.
While the market talks about AI drug discovery, Tempus is doing something more fundamental — turning clinical data into an asset that can be sold over and over. The question is: will this money-printing machine actually start printing?
TTD has fallen 55% from its high, but the CEO's $148 million share purchase, OpenAI partnership rumors, and CTV's structural shift are igniting a rebound all at once. But with growth slowing to ~10%, the boundaries of any valuation recovery are clearly visible.
In the 2026 AI investing game, the bottleneck determining compute profits is a physical limit — power and cooling. Through three nonlinear amplification effects — power density, system complexity, and risk transfer — Vertiv (VRT) has become the party hyperscalers outsource their SLA liability to, making it one of the hardest names to route around in AI infrastructure.